More about
Cell Death
Clinical Guidance
Non-Small Cell Lung Cancer
Overview
Pathogenesis and Pathophysiology
News
December 01, 2020
3 min read
Save
Q&A: Aducanumab, one of 121 experimental AD drugs in clinical trials, awaits FDA approval
In early November, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee met to discuss a Biologics License Application for aducanumab, an anti-amyloid antibody in development for Alzheimer’s disease.